Astrazeneca Plc Adr Stock Working Capital
| AZN Stock | USD 68.36 0.17 0.25% |
AstraZeneca PLC ADR fundamentals help investors to digest information that contributes to AstraZeneca PLC's financial success or failures. It also enables traders to predict the movement of AstraZeneca Stock. The fundamental analysis module provides a way to measure AstraZeneca PLC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to AstraZeneca PLC stock.
| Last Reported | Projected for Next Year | ||
| Net Working Capital | -5.5 B | -5.2 B | |
| Change In Working Capital | 300 M | 177.9 M | |
| Working Capital | 3.5 B | 1.8 B |
AstraZeneca | Working Capital |
AstraZeneca PLC ADR Company Working Capital Analysis
AstraZeneca PLC's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current AstraZeneca PLC Working Capital | (5.49 B) |
Most of AstraZeneca PLC's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AstraZeneca PLC ADR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
AstraZeneca Working Capital Driver Correlations
Understanding the fundamental principles of building solid financial models for AstraZeneca PLC is extremely important. It helps to project a fair market value of AstraZeneca Stock properly, considering its historical fundamentals such as Working Capital. Since AstraZeneca PLC's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of AstraZeneca PLC's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of AstraZeneca PLC's interrelated accounts and indicators.
Click cells to compare fundamentals
AstraZeneca Working Capital Historical Pattern
Today, most investors in AstraZeneca PLC Stock are looking for potential investment opportunities by analyzing not only static indicators but also various AstraZeneca PLC's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's working capital growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of AstraZeneca PLC working capital as a starting point in their analysis.
AstraZeneca PLC Working Capital |
| Timeline |
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
AstraZeneca Capital Stock
Capital Stock |
|
In accordance with the company's disclosures, AstraZeneca PLC ADR has a Working Capital of (5.49 Billion). This is 1389.32% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The working capital for all United States stocks is significantly higher than that of the company.
AstraZeneca Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses AstraZeneca PLC's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of AstraZeneca PLC could also be used in its relative valuation, which is a method of valuing AstraZeneca PLC by comparing valuation metrics of similar companies.AstraZeneca PLC is currently under evaluation in working capital category among related companies.
AstraZeneca Fundamentals
| Return On Equity | 0.16 | ||||
| Return On Asset | 0.066 | ||||
| Profit Margin | 0.13 % | ||||
| Operating Margin | 0.17 % | ||||
| Current Valuation | 130.04 B | ||||
| Shares Outstanding | 3.1 B | ||||
| Shares Owned By Institutions | 16.80 % | ||||
| Number Of Shares Shorted | 7.66 M | ||||
| Price To Earning | 103.39 X | ||||
| Price To Book | 5.46 X | ||||
| Price To Sales | 4.67 X | ||||
| Revenue | 45.81 B | ||||
| Gross Profit | 35.73 B | ||||
| EBITDA | 13.91 B | ||||
| Net Income | 6.9 B | ||||
| Cash And Equivalents | 4.52 B | ||||
| Cash Per Share | 1.46 X | ||||
| Total Debt | 28.62 B | ||||
| Debt To Equity | 0.89 % | ||||
| Current Ratio | 0.81 X | ||||
| Book Value Per Share | 25.25 X | ||||
| Cash Flow From Operations | 10.35 B | ||||
| Short Ratio | 1.61 X | ||||
| Earnings Per Share | 1.91 X | ||||
| Price To Earnings To Growth | 0.89 X | ||||
| Target Price | 81.81 | ||||
| Number Of Employees | 89.9 K | ||||
| Beta | 0.19 | ||||
| Market Capitalization | 211.61 B | ||||
| Total Asset | 101.12 B | ||||
| Retained Earnings | 1.5 B | ||||
| Working Capital | (5.49 B) | ||||
| Current Asset | 16.01 B | ||||
| Current Liabilities | 14.87 B | ||||
| Annual Yield | 0.02 % | ||||
| Five Year Return | 2.99 % | ||||
| Net Asset | 101.12 B | ||||
| Last Dividend Paid | 2.9 |
About AstraZeneca PLC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AstraZeneca PLC ADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AstraZeneca PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AstraZeneca PLC ADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
AstraZeneca PLC Investors Sentiment
The influence of AstraZeneca PLC's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in AstraZeneca. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to AstraZeneca PLC's public news can be used to forecast risks associated with an investment in AstraZeneca. The trend in average sentiment can be used to explain how an investor holding AstraZeneca can time the market purely based on public headlines and social activities around AstraZeneca PLC ADR. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
AstraZeneca PLC's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for AstraZeneca PLC's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average AstraZeneca PLC's news discussions. The higher the estimated score, the more favorable is the investor's outlook on AstraZeneca PLC.
AstraZeneca PLC Implied Volatility | 41.6 |
AstraZeneca PLC's implied volatility exposes the market's sentiment of AstraZeneca PLC ADR stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if AstraZeneca PLC's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that AstraZeneca PLC stock will not fluctuate a lot when AstraZeneca PLC's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards AstraZeneca PLC in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, AstraZeneca PLC's short interest history, or implied volatility extrapolated from AstraZeneca PLC options trading.
Pair Trading with AstraZeneca PLC
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AstraZeneca PLC position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AstraZeneca PLC will appreciate offsetting losses from the drop in the long position's value.Moving together with AstraZeneca Stock
| 0.75 | YS | YS Biopharma Report 22nd of April 2024 | PairCorr |
Moving against AstraZeneca Stock
| 0.77 | VCNX | Vaccinex | PairCorr |
| 0.68 | DRTS | Alpha Tau Medical Financial Report 28th of May 2024 | PairCorr |
| 0.66 | DMTK | DermTech Financial Report 2nd of May 2024 | PairCorr |
| 0.65 | DRUG | Bright Minds Biosciences | PairCorr |
| 0.63 | KA | Kineta Inc Financial Report 9th of May 2024 | PairCorr |
The ability to find closely correlated positions to AstraZeneca PLC could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AstraZeneca PLC when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AstraZeneca PLC - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AstraZeneca PLC ADR to buy it.
The correlation of AstraZeneca PLC is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AstraZeneca PLC moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AstraZeneca PLC ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AstraZeneca PLC can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out AstraZeneca PLC Piotroski F Score and AstraZeneca PLC Altman Z Score analysis. Note that the AstraZeneca PLC ADR information on this page should be used as a complementary analysis to other AstraZeneca PLC's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Complementary Tools for AstraZeneca Stock analysis
When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |
Is AstraZeneca PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AstraZeneca PLC. If investors know AstraZeneca will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AstraZeneca PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.059 | Dividend Share 2.9 | Earnings Share 1.91 | Revenue Per Share 2.4547 | Quarterly Revenue Growth 0.073 |
The market value of AstraZeneca PLC ADR is measured differently than its book value, which is the value of AstraZeneca that is recorded on the company's balance sheet. Investors also form their own opinion of AstraZeneca PLC's value that differs from its market value or its book value, called intrinsic value, which is AstraZeneca PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AstraZeneca PLC's market value can be influenced by many factors that don't directly affect AstraZeneca PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AstraZeneca PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if AstraZeneca PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AstraZeneca PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.